GLP-1 Users Who Added Omada's Program Lost Twice the Fat and Kept More Muscle
A 12-week study found Omada's wraparound GLP-1 program doubled fat loss and nearly tripled muscle preservation vs. controls.
Summary
A new study from Omada Health compared 151 members enrolled in its GLP-1 Care Track against 94 people taking GLP-1 medications alone. Over 12 weeks, Omada members lost 6% of body weight versus 3.3% in controls, reduced body fat by 3.3% compared to roughly half that in controls, and increased muscle mass percentage nearly three times more. The program combines human coaching, personalized strength training, and digital tracking tools designed to improve body composition quality — not just scale weight. Members also reported better mental health, physical function, and confidence. For anyone on GLP-1 medications, this suggests that structured lifestyle support may significantly improve how that weight is lost, preserving the muscle that matters most for long-term metabolic health and function.
Detailed Summary
GLP-1 medications like semaglutide have transformed weight loss, but a persistent concern is that they can cause significant muscle loss alongside fat. Omada Health's new study directly addresses this by testing whether a structured support program can improve the quality of weight lost — not just the quantity.
The 12-week study followed 245 adults with obesity (BMI ≥30): 151 enrolled in Omada's GLP-1 Care Track and 94 controls who had recently started a GLP-1 on their own. Omada members lost an average of 6.0% of starting body weight versus 3.3% for controls — a 1.8-fold difference. More strikingly, Omada members reduced body fat percentage by 3.3%, roughly twice the reduction seen in controls, and increased their muscle mass percentage nearly threefold compared to the control group.
The GLP-1 Care Track is a wraparound digital health program combining human care teams, personalized strength-focused exercise programming, and digital tools including at-home smart scales for tracking weight and body composition. Participants also completed surveys measuring mental health, well-being, self-efficacy, and physical function — all of which showed greater improvements in the Omada group.
These findings matter because muscle mass is a critical longevity biomarker. Preserving lean mass during weight loss protects metabolic rate, insulin sensitivity, physical function, and long-term independence. If GLP-1 users can nearly triple their muscle preservation simply by adding structured coaching and resistance training, the implications for healthspan — not just weight — are substantial.
Important caveats apply. This is a company-funded, non-randomized comparative study, not a peer-reviewed randomized controlled trial. The control group was not matched through random assignment, introducing potential selection bias. Body composition was measured via consumer-grade at-home scales, which are less accurate than DEXA scanning. Independent replication in a rigorous trial setting is needed before strong clinical conclusions can be drawn.
Key Findings
- Omada GLP-1 Care Track members lost 6.0% body weight vs. 3.3% in controls over 12 weeks
- Body fat percentage dropped 3.3% in Omada members — roughly twice the reduction seen in controls
- Muscle mass percentage increased nearly 3x more in Omada members than in the control group
- Program combines human coaching, strength-focused exercise, and digital tools to protect lean mass
- Members also reported greater improvements in mental health, physical function, and weight-loss confidence
Methodology
This is a company-funded research summary from Omada Insights Lab ANSWERS, not yet published in a peer-reviewed journal. The study is a non-randomized comparative design with 245 participants, limiting causal inference. Body composition was measured using consumer at-home scales rather than gold-standard DEXA, which reduces measurement precision.
Study Limitations
This is a non-randomized, company-sponsored study without peer review, meaning selection bias cannot be ruled out. Body composition tracking relied on consumer-grade at-home scales rather than DEXA or clinical-grade tools, reducing data reliability. Independent replication in a randomized controlled trial is needed to confirm these findings.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.